Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cambodia phase 4 therapeutic efficacy study of dihydroartemisinin-piperaquine and artesunate-mefloquine for uncomplicated falciparum malaria
ACTRN12612000182897Phase 4Active, not recruiting
- Sponsor
- The Global Fund to Fight AIDS, Tuberculosis and Malaria
- Start
- Aug 2011
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dihydroartemisinin, piperaquine, artesunate and mefloquine in malaria and Falciparum malaria (PF) (2 arms), sponsored by The Global Fund to Fight AIDS, Tuberculosis and Malaria. Primary endpoints: 42-day cure rate or adequate clinical and parasitological response and 42-day PCR-corrected ACPR. Started Aug 2011; status: active, not recruiting.
02
Drugs
dihydroartemisininpiperaquineartesunatemefloquine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ACTRN12612000182897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000182897.